Hortobagyi GN - Search Results

1

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Oncogene. 1998 Jun 4;16(22):2855-63. doi: 10.1038/sj.onc.1201813. Oncogene. 1998. PMID: 9671406

2

The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.

Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. Chang JY, et al. Among authors: hortobagyi gn. Oncogene. 1997 Feb 6;14(5):561-8. doi: 10.1038/sj.onc.1200861. Oncogene. 1997. PMID: 9053854

3

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Yu D, et al. Among authors: hortobagyi gn. Oncogene. 1998 Apr 23;16(16):2087-94. doi: 10.1038/sj.onc.1201729. Oncogene. 1998. PMID: 9572489

4

A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

Hortobagyi GN, Hung MC, Lopez-Berestein G. Hortobagyi GN, et al. Hum Gene Ther. 1998 Aug 10;9(12):1775-98. doi: 10.1089/hum.1998.9.12-1775. Hum Gene Ther. 1998. PMID: 9721088 Clinical Trial. No abstract available.

5

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Zhang L, et al. Among authors: hortobagyi gn. Clin Cancer Res. 1999 Feb;5(2):343-53. Clin Cancer Res. 1999. PMID: 10037184

6

Recent developments in breast cancer therapy.

Hortobagyi GN, Hung MC, Buzdar AU. Hortobagyi GN, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):11-20. Semin Oncol. 1999. PMID: 10482190 Review.

7

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

8

Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.

Hung MC, Hortobagyi GN, Ueno NT. Hung MC, et al. Among authors: hortobagyi gn. Adv Exp Med Biol. 2000;465:171-80. doi: 10.1007/0-306-46817-4_16. Adv Exp Med Biol. 2000. PMID: 10810625 Review. No abstract available.

9

Developments in chemotherapy of breast cancer.

Hortobagyi GN. Hortobagyi GN. Cancer. 2000 Jun 15;88(12 Suppl):3073-9. doi: 10.1002/1097-0142(20000615)88:12+<3073::aid-cncr26>3.3.co;2-i. Cancer. 2000. PMID: 10898354 Review.

10

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.

Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Hortobagyi GN, et al. J Clin Oncol. 2001 Jul 15;19(14):3422-33. doi: 10.1200/JCO.2001.19.14.3422. J Clin Oncol. 2001. PMID: 11454891 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,108 results

Search Page

Filters